Family · Pharmaceutical analytical standards
Resmetirom
A selective thyroid hormone receptor beta agonist, approved in the United States in March 2024 as the first medicine for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis; it reached Europe in 2025. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It mimics thyroid hormones only where needed: the beta receptor is the most abundant one in the liver, where it helps burn fat, while the alpha receptor, which dominates in the heart and bones, is largely spared.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
